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Abstract
Abnormalities of motivation and behavior in the context of reward are a fundamental component of addiction and mood
disorders. Here we test the effect of a functional missense mutation in the dopamine 3 receptor (DRD3) gene (ser9gly,
rs6280) on reward-associated dopamine (DA) release in the striatum. Twenty-six healthy controls (HCs) and 10 unmedicated
subjects with major depressive disorder (MDD) completed two positron emission tomography (PET) scans with
[11C]raclopride using the bolus plus constant infusion method. On one occasion subjects completed a sensorimotor task
(control condition) and on another occasion subjects completed a gambling task (reward condition). A linear regression
analysis controlling for age, sex, diagnosis, and self-reported anhedonia indicated that during receipt of unpredictable
monetary reward the glycine allele was associated with a greater reduction in D2/3 receptor binding (i.e., increased reward-
related DA release) in the middle (anterior) caudate (p,0.01) and the ventral striatum (p,0.05). The possible functional
effect of the ser9gly polymorphism on DA release is consistent with previous work demonstrating that the glycine allele
yields D3 autoreceptors that have a higher affinity for DA and display more robust intracellular signaling. Preclinical
evidence indicates that chronic stress and aversive stimulation induce activation of the DA system, raising the possibility
that the glycine allele, by virtue of its facilitatory effect on striatal DA release, increases susceptibility to hyperdopaminergic
responses that have previously been associated with stress, addiction, and psychosis.
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Introduction
Abnormalities of motivation and behavior in the context of
reward are a key component of addiction and mood disorders.
While the neurophysiological structure of the ‘‘reward circuit’’ has
been well delineated (figure 1), the genetic contribution to striatal
dopaminergic signaling remains poorly understood. Using positron
emission tomography (PET), a number of groups have reported
associations between functional variants in the DRD2 gene and
the binding potential (BP) of [11C]raclopride, a D2/3 antagonist
[1,2,3,4]. The BP parameter reflects the density x the affinity of
D2/3 receptors in the brain. These imaging data are potentially
important because genetically-driven differences in dopamine
(DA) receptor function may influence the changes in dopaminergic
signaling that modulate emotional, motivational and stress
responses.
In contrast, the impact of genetic variation in the DRD3 gene
on measures of DA receptor binding or function has received little
attention in the PET literature. Unlike D1 and D2 receptors, the
D3 receptor is largely expressed on the dopaminergic neurons of
the nucleus accumbens (NAc) [5] where it acts as a DA release-
regulating autoreceptor (the D3 receptor has also been shown to
act as a heteroreceptor) [6]. Other regions in which the D3
receptor is expressed include the substantia nigra, hypothalamus,
globus pallidus, and thalamus [7,8]. In preclinical studies,
blockade of the D3 receptor has been reported to reduce
relapse after the presentation of conditioned alcohol and
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nicotine-associated cues [9,10] and to prevent the stress-induced
reinstatement of cocaine-seeking behavior [11]. In humans,
postmortem work showed that the density of D3 receptors was
elevated in cocaine abusers [12] while polymorphisms of DRD3
gene have been associated with smoking behavior [13,14], nicotine
dependence [15], and alcohol craving [16]. Polymorphisms of the
DRD3 gene also have been implicated in increasing the risk for
major depressive disorder (MDD) [17,18].
Stress-induced anhedonia, the failure to experience pleasure in
appropriate contexts, has been associated with decreased respon-
siveness of the D3 receptor in the NAc in animal models;
conversely multiple classes of antidepressant medications as well as
electroconvulsive therapy (ECT) enhance D3 receptor responsive-
ness [19,20,21].. Consistent with these data, genetic variants in the
DRD3 gene were associated with differential responsiveness to
ECT in humans with major depressive disorder (MDD) [22].
Notably, pramipexole, a dopamine receptor agonist with high
selectivity for the D2 dopamine receptor family and preferential
affinity for the D3 receptor subtype, has shown antidepressant
effects in humans [23,24] and has been reported to augment tonic
DA release and to alter DA neuronal firing activity in rodents [25].
Pharmacogenetic studies have reported that a functional single
nucleotide polymorphism (SNP) in the DRD3 gene (ser9gly)
influenced antidepressant response in bipolar disorder patients
treated with a combination of olanzapine and fluoxetine [26] as
well as response to paroxetine in patients with MDD [27]. The
ser9gly polymorphism has also been associated with depression
arising in the context of dementia [28] as well as primary MDD
[17,29,30].
A potentially informative measure of the effect of DRD3
polymorphisms on central dopaminergic function is afforded by
the sensitivity of [11C]raclopride binding to endogenous DA
release [31], given the prominent role of the D3 receptor in
regulating DA release in the ventral striatum [6]. This PET-
[11C]raclopride technique thus allows exploration of the effects of
genetic variation on the amount of DA released under conditions
associated with increased phasic release of DA, such as during
receipt of unpredicted reward [32]. Since DA is released in the
NAc in response to unpredicted reward [33], the degree of
displacement of [11C]raclopride by the increase in intrasynaptic
DA concentrations during reward would then be evident by
changes in the radioligand binding to either D2 or D3 receptors
[34,35].
Notably, the application of the PET-[11C]raclopride imaging to
measure the degree of DA release during reward provides an
experimental paradigm that is sensitive to potential functional
effects of genetic variation in the D3 receptor, despite the fact that
at baseline, the [11C]raclopride signal is dominated by the D2
receptor. [11C]Raclopride shows not only a modestly greater
affinity for the D2 receptor compared with the D3 receptor [36],
but relative to the D3 receptor, the density of the D2 receptor is
approximately 2-fold greater in the NAc and 4-fold greater in the
Figure 1. The phasic burst-firing activity of DA neurons in the VTA is induced by direct excitatory input from the PPTg to the VTA.
(Adapted from Grace et al. 2007). Tonic firing (population firing) is regulated by a loop consisting of the vSub, NAc, VP, and VTA. Activation of the
vSub, either directly or via the BLA drives NAc-mediated disinhibition of the VTA, resulting in tonic DA release. Burst-firing can only occur in the
proportion of the DA neuron population that is tonically active prior to the arrival of afferent excitatory transmission from the mPFC or the PPTg.
BLA=basolateral amygdala, mPFC=medial prefrontal cortex, NAc =nucleus accumbens, PPTg=peduculopontine tegmentum, VP= ventral pallidum,
vSub= ventral subiculum, VTA= ventral tegmental area. Red arrows= glutamatergic projections, blue arrows =GABAergic projections, green
arrow=dopaminergic projections.
doi:10.1371/journal.pone.0054108.g001
DRD3 Ser9Gly SNP Affects Reward Processing
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e54108
caudate at postmortem [37]. More recent in vivo studies using [11C]-
(+)-PHNO, a radioligand that binds preferentially to the D3
receptor, have indicated that in the absence of reward, the D3
receptor accounts for less than 10% of the signal in the striatum
and caudate [7,8]. Thus the D3 receptor binding contributes only
a fraction of the baseline [11C]raclopride BP rendering this
measure relatively insensitive to genetically-mediated differences in
D3 receptor binding (which would likely be masked by noise
introduced by variations in D2 receptor phenotype).
In healthy controls (HC), we previously assessed the magnitude
of reward-associated DA release with PET by measuring
differences in D2/D3 receptor BPND (DBPND) for [
11C]raclopride
between an unpredictable monetary reward condition and a
sensorimotor control condition [38]. A decrease in BPND,
indicative of increased endogenous DA release, was observed in
the ventral striatum and left middle caudate region-of-interest
(anterior caudate head) regions-of-interest in the reward versus the
control condition [38]. We also found a significant reduction in
[11C]raclopride BPND in depressed patients versus HCs in the
anteroventral striatum (unpublished data). Here we tested the
effect of a functional missense mutation in the DRD3 gene
(ser9gly, rs6280) on DBPND in the caudate and striatum in healthy
individuals and MDD patients who completed PET scanning with
[11C]raclopride.
Patients and Methods
Subject Data
Subjects provided written informed consent after receiving a full
explanation of the study procedures and risks, as approved by the
NIMH IRB. Twenty-six right-handed HCs (15 women; mean age
34.468.3) and 10 currently depressed, unmedicated patients with
MDD (8 women; mean age 38.2611.3) participated in the study
(table 1). Handedness was assessed using the Edinburgh Handed-
ness Inventory. A medical history, physical examination, labora-
tory testing (including drug screening), T1-weighted MRI, and
both structured (Structured Clinical Interview for the DSM-IV-
TR) and an unstructured (with a psychiatrist) psychiatric
interviews were obtained on all participants. Anhedonic symptoms
were rated using the Snaith-Hamilton Pleasure Scale (SHAPS).
Volunteers were excluded if they had taken antidepressant
medications or other drugs likely to affect cerebral physiology,
monoaminergic neurotransmitter function, or vascular function
within 3 weeks of the scan (8 weeks for fluoxetine). Other exclusion
criteria included having: a major medical or neurological disorder;
a history of psychosis; illicit drug use or alcohol abuse within one
year of the scan; lifetime history of alcohol or drug dependence;
lifetime exposure to stimulant drugs (e.g., cocaine, amphetamines)
tobacco use within 1 year of the scan; lifetime history of
pathological gambling behavior as assessed with the lie/bet screen
and South Oaks Gambling Screen (SOGS), electrolyte distur-
bance, anemia, positive drug test or HIV screen on laboratory
testing, IQ,85; current pregnancy or breast feeding, and general
MRI exclusions. Additional exclusions applied to the healthy
group included having met DSM-IV-TR criteria for a current or
past psychiatric disorder or having a first degree relative with a
mood or anxiety disorder as established using the Family Interview
for Genetic Studies (FIGS).
PET Imaging
The Sensorimotor and Gambling (Slot Machine)
Tasks. Methodological details can be found in [38]. Briefly,
the slot machine task involved two conditions, each consisting of
180 trials, each of average duration 8 sec. In the monetary-reward
condition subjects received financial rewards unpredictably, in a
pseudo-randomized order with an average of one reward per four
trials. In the sensorimotor control condition subjects performed the
same task without receiving rewards, to control for motor
activation or other nonspecific aspects of task-performance (figure
S1).
During scanning subjects initially rested for 20 min in order to
allow [11C]raclopride to approach equilibrium (previously vali-
dated by [39,40]), and thereafter they performed the sensorimotor
control task for approximately 24 min. Beginning 50 min after the
start of the [11C]raclopride infusion, subjects performed the
monetary reward condition for approximately 24 min. This timing
allowed the distribution of [11C]raclopride to come into equilib-
rium for each of the two task conditions. During the 24 min
epochs that corresponded to each task condition, subjects
alternated between two-min periods in which they actively
performed the task and one-min periods when they rested to
minimize fatigue. Each subject won a total of $33 during the
rewarded condition.
Image Acquisition. PET scans were acquired using a GE-
Advance scanner in 3D-mode (3D resolution = 6 mm full-width at
half-maximum). The data were reconstructed using a Hanning-
filter and Gaussian-fit scatter-correction method. A transmission
scan was acquired using rotating 68Ge/68Ga rods to perform
attenuation-correction of the emission scans. The [11C]raclopride
(20 mCi) was administered as an initial bolus over 60 seconds
followed by a maintenance infusion over the remainder of the
scanning session using a computer-controlled pump. Dynamic
emission scanning (27 frames) was initiated with injection of the
[11C]raclopride bolus. MRI images were acquired on a General
Electric 3.0 Tesla scanner (GE Healthcare, Waukesha, WI), using
T1 weighted sequences to provide an anatomical framework for
image analysis (in-plane resolution: 0.86 mm, slice thickness:
1.2 mm).
PET Image Analysis. Mean tissue radioactivity concentra-
tions from the baseline and reward images were extracted using
MRI-based regions-of-interest (ROI), defined on a template MRI
image using MEDx software in the anteroventral striatum, middle
caudate, and cerebellum after Martin-Soelch et al. (2011). Each
individual’s MRI was registered to a template brain and the ROIs
were repositioned as needed to accommodate individual differ-
ences in anatomy. The anatomical accuracy of each set of
individual ROI was verified by a neuroscientist familiar with
striatal anatomy (WCD). These ROIs then were back-transformed
into the subject’s native MRI space and applied to the co-
registered PET images.
Decay-corrected, tissue radioactivity concentrations (C) were
obtained from each ROI using a calibrated phantom standard to
convert tomographic counts to Bq/ml. Mean radioactivity in the
reference region (cerebellum; C9) was used to factor out the effects
of free and non-specifically bound [11C]raclopride. The percent
change in [11C]raclopride binding was computed as the difference
in BPND (C/C9-1 for each ROI) between baseline and reward
images.
Selection of Regions of Interest. The ventral striatum and
middle caudate were chosen as ROIs on the basis of our previously
published imaging findings regarding the striatal subregions where
[11C]raclopride binding changed in response to unpredicted
monetary reward [38]. The ROIs in [38] were defined using
neuroanatomical landmarks on the co-registered MRI scan after
the method described by [41]. In primates the cells with
histochemical and connectional features of the NAc shell
implicated in reward learning are scattered through the accum-
bens area, ventromedial caudate, and anteroventral putamen [42],
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and previous PET studies of amphetamine-induced DA release
showed that euphoria correlated with DA release in the
anteroventral striatum and ventral putamen [41,43]. The middle
caudate consists of the central portion of the anterior caudate
head, which receives anatomical projections from the orbitofrontal
and ventromedial prefrontal cortical regions implicated in reward
processing [44].
Genotyping
Samples were genotyped for the rs6280 polymorphism using the
Illumina GoldenGate platform [45]. The array covers 130
candidate genes for alcoholism, other addictions, and mood and
anxiety disorders. The average call rate of this platform is 98.3%
and the replication rate, 99.7%. The array also allows for control
of population stratification through the inclusion of 186 ancestry
informative markers (AIMs). The AIMs panel identifies six distinct
groups from the global population, based upon geographic
relationships: Europe, Africa, Middle East, Asia, Far East Asia,
Oceania, and the Americas.
Statistical Analysis
To test whether ethnicity predicted D3 [11C]raclopride binding,
we used African and European ancestry, defined by genetically
informative markers, as predictors of [11C]raclopride binding in
separate regression models. There was no effect of either African
or European ancestry on baseline BPND of ventral striatum and
middle caudate as well as D BPND of the ventral striatum and
middle caudate (table S1). The majority of the participants were
Caucasian or African American and thus the ancestry categories,
Middle-Eastern, Asian, Far East Asian, Oceania, and America
were not evaluated as predictors of raclopride binding because
these factors were quantitatively negligible across the sample.
Imaging genetics data were analyzed with a 2-step forced linear
regression. The following predictor variables were entered into the
model: age, sex, diagnosis, and SHAPS score (step 1) and ser9gly
genotype (ser/ser vs ser/gly vs gly/gly) (step 2). Baseline BPND of
ventral striatum and middle caudate as well as D BPND of the
ventral striatum and middle caudate constituted the dependent
variables.
Hardy-Weinberg Equilibrium (HWE) was tested using Haplo-
view [46]. Thirteen subjects were homozygous for the serine allele,
11 subjects were heterozygotes, and 12 subjects were homozygous
for glycine.
Results
The ser9gly SNP was not significantly associated with [11C]ra-
clopride binding in the ventral striatum or middle caudate at
baseline (table 2). However, a linear regression analysis controlling
for age, sex, diagnosis, and self-reported anhedonia indicated that
during receipt of unpredictable monetary reward the glycine allele
was associated with a greater reduction in D2/3 receptor binding
(i.e. increased reward-related DA release) in the middle caudate (r2
explained = 0.24, b-weight = 0.5, t = 3.3, p = 0.003) and the
ventral striatum (r2 explained = 0.14; b-weight = 0.4, t = 2.3,
p = 0.027) (fig. 2, table 2). A similar, but not statistically significant
pattern of findings was observed when the MDD group was
considered separately from the HC group (figure, S2).
The ser9gly polymorphism was not in HWE (p= 0.0346) most
likely because of the small sample size. Although ethnic
stratification is also a possible cause of the divergence of the
Ser9Gly polymorphism from HWE, [11C]raclopride binding was
not affected by ethnic origin (table S1) suggesting that our results
are not confounded by population admixture.
Table 1. Demographic and Clinical Data for MDD and HC Groups (A) and Total Sample Stratified by Genotype (B).
A MDD HC
N 10 26
Gender (M/F) 2/8 11/15
Age 38.2611.3 34.568.3
MADRS 24.368.2 0.661.6
HAM-A 12.966.6 0.761.6
Chapman-P 20.0610.5 8.065.1
Chapman-S 18.269.2 5.663.9
SHAPS 32.367.7 20.166.5
B SER/SER SER/GLY GLY/GLY
N 13 11 12
Diagnosis (MDD/HC) 4/9 4/7 2/10
Gender (M/F) 4/9 5/6 4/8
Age 35.269.5 39.0611.0 32.666.3
Baseline BPND: VS 4.2461.00 4.4361.01 3.8561.21
Baseline BPND: MC 3.7760.94 3.7561.07 3.5661.11
D BPND: VS 0.4567.34 22.1566.73 26.4668.07
D BPND: MC 2.6767.79 22.0965.90 25.7065.10
Note: D BPND= Change in Raclopride Binding Between Baseline Sensorimotor and Gambling Task; Chapman-P = Chapman Physical Anhedonia Rating Scale; Chapman-
S =Chapman Social Anhedonia Rating Scale; F = Female; HAM-A=Hamilton Anxiety Scale; HC=Healthy Control; M =Male; MADRS =Montgomery-Asberg Depression
Rating Scale; MC=Middle Caudate; VS = Ventral Striatum; MDD=Major Depressive Disorder; SHAPS = Snaith-Hamilton Pleasure Scale.
doi:10.1371/journal.pone.0054108.t001
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Discussion
A potential neurobiological mechanism of ser9gly DA
signaling modulation
Our finding that the glycine allele is associated with greater
reward-related DA release is potentially consistent with an in vitro
study showing that the glycine allele yields D3 autoreceptors that
have a higher affinity for DA in both G-protein-coupled and
uncoupled receptor states and show more robust cAMP and
MAPK signaling [47].
Electrophysiology studies demonstrate that DA neurons in the
ventral tegmental area (VTA) are either inactive, display irregular
tonic-firing, or show phasic burst-firing patterns. In response to
unpredicted reward the population of DA neurons engaged in
burst-firing increases, although only those DA neurons that had
been active prior to stimulation are able to burst-fire in response to
excitatory afferent input [48]. The D3 receptor is densely
distributed in the shell region of the NAc where it predominantly
acts as a presynaptic autoreceptor that inhibits DA release. The
higher affinity of the glycine D3 autoreceptor would be expected
to decrease the extrasynaptic DA concentration under conditions
of tonic DA release, potentially diminishing the inhibitory tone on
the amount of DA released per action potential during burst firing,
and thereby enabling an increase in the efficacy with which burst-
firing releases DA (i.e., more neurotransmitter released per action
potential) [49].
The higher affinity of the glycine autoreceptor may also
predispose to elevated phasic DA signaling – i.e. greater reward-
associated DA release – via a second mechanism. In rodents the
tonic firing activity of VTA DA neurons is regulated by
antagonistically-acting afferent projections to the NAc from the
medial prefrontal cortex (mPFC) and ventral subiculum (vSub)
(figure 1). D2/3 receptor stimulation selectively inhibits mPFC
inputs to the NAc while D1 receptor agonists increase NAc activity
via the vSub [48]. More specifically, excitatory projections from
the vSub release inactive DA neurons from inhibition, by
stimulating the inhibitory projection from the NAc to the ventral
pallidum, thereby increasing the pool of DA neurons available for
burst-firing [48]. The D1 and D3 receptors form dimers in the
limbic and associative striatum allowing for synergistic interaction
[50], such that higher affinity D3 receptors, by augmenting phasic
DA release, could theoretically potentiate hippocampal drive and
thus increase the population of DA neurons entering a burst-firing
pattern in response to rewarding stimuli. One would therefore
expect a D3 receptor with higher affinity for DA to result in
greater DA release during phasic burst-firing.
Potential clinical implications
Depression and/or anhedonia has been shown to be associated
with a reduced striatal response to reward [reviewed in [44,51]].
These data are primarily derived from hemodynamic imaging
methods, especially functional MRI (fMRI). The BOLD fMRI
signal reflects the corresponding change in regional cerebral blood
flow associated with synaptic terminal field metabolic activity and
is dominated by glutamatergic transmission, with a relatively
smaller component attributable to GABAergic transmission [52].
In contrast, the proportion of the BOLD signal that reflects a
direct contribution of terminal field metabolic activity of
monoaminergic (i.e., DA) neurons is negligible [52]. Within the
striatum many of the DA projections synapse directly on the axon
terminals of glutamatergic neurons, and DA release acts to inhibit
glutamate release from the afferent excitatory projections [53,54],
Thus an increase in striatal DA signaling could potentially account
for the reduction in the BOLD striatal response to reward
observed in the ventral striatum in depressed MDD subjects.
These data raise the possibility that the glycine allele, which is
associated with increased reward-associated DA release, predis-
poses to the development of mood disorders. Indeed we found that
among the MDD patients glycine allele carriers were more
anhedonic (measured with the Chapman Social Anhedonia Scale)
than serine/serine homozygotes (data not shown). This association
between the glycine allele and anhedonia is potentially consistent
with preclinical data that indicate that chronic stress and aversive
stimulation induce a pronounced activation of the DA system both
electrophysiologically (number of DA neurons firing spontaneous-
ly) and behaviorally (response to psychostimulants), driven by
hyperactivity within the ventral hippocampus [55].
Theoretically, the glycine allele-associated increase in phasic
DA signaling may also contribute to the development of addiction
disorders. Pharmacological agents that induce feelings of pleasure
are known to stimulate DA release in the ventral striatum
(reviewed in [56]). In addition, as discussed in Joutsa et al. [57], the
binding of [11C]raclopride is sensitive to changes in striatal DA
concentration during receipt of non-pharmacological rewards such
as a video game [58], large monetary wins versus large monetary
losses [59] and the monetary incentive delay task [60]. Notably, in
a study of pathological gamblers and healthy controls who
completed 3 PET scans with [11C]raclopride while gambling with
a slot machine, the severity of addiction to gambling was positively
associated with the degree of DA release in the basal ganglia
during gambling [57]. Consistent with these results, highly
impulsive individuals, who are thought to be vulnerable to
developing addiction disorders, were shown to have diminished
Table 2. Linear Regression Showing Effects of Ser9Gly on Raclopride Binding and Anhedonia Scores.
Predictors Ser9Gly R2 Explained Beta-Weight T-Score P-Value
Durbin-
Watson VIF
Baseline BPND: VS a 0.043 0.22 1.3 0.202 2.2 1.07
Baseline BPND: MC a 0.018 0.14 0.9 0.399 2.1 1.07
D BPND: VS a 0.142 0.39 2.3 0.027* 2.0 1.07
D BPND: MC a 0.235 0.50 3.3 0.003** 2.1 1.07
Note: BPND =Non-Displaceable Binding Potential; D BPND =Change in Raclopride Binding Potential Between Baseline Sensorimotor and Gambling Task; Chapman
P=Chapman Physical Anhedonia Rating Scale; Chapman S=Chapman Social Anhedonia Rating Scale; MC=Middle Caudate; SHAPS = Snaith-Hamilton Pleasure Scale;
VS = Ventral Striatum.
a= age, sex, diagnosis, SHAPS score, and DRD3 ser9gly (ser/ser vs ser/gly vs gly/gly) in combined sample.
* = p,0.05.
** = p,0.01.
doi:10.1371/journal.pone.0054108.t002
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availability of striatal D2/3 autoreceptors, potentially predisposing
them to a greater phasic DA response [61].
In preclinical models of substance abuse, stress-induced
elevations in glucocorticoids result in an increased response to
psychostimulants while administration of glucocorticoid antago-
nists or adrenalectomy attenuates self-administration of psycho-
stimulants [62,63]. In healthy humans, cortisol levels were found
to be positively correlated with amphetamine-induced DA release
measured with [11C]raclopride in the ventral striatum and the
dorsal putamen [64]. These data, taken together with the findings
presented here, thus suggest the hypothesis that the susceptibility
for developing hyperdopaminergic responses to stress in carriers of
the glycine allele may be accentuated in individuals with
hypercortisolemia.
Potential treatment implications
The important role of DA signaling in mood disorders is
congruent with the fact that pramipexole, a medication with
antidepressant properties that selectively binds to the D3 receptor,
has been reported to augment tonic DA release and to alter the
sensitivity of D3 autoreceptors in rodents [25]. Interestingly, Liu et
al. [65] reported that Parkinson’s disease patients homozygous for
Figure 2. Scatterplots of the percent change in D2/D3 receptor binding in the reward versus baseline condition for the middle
caudate and the ventral striatum. The mean change in D2/D3 receptor binding for each group is represented by the red square and the standard
error of the mean is shown with the error bars. Negative values are indicative of greater dopamine release in the reward versus baseline condition.
doi:10.1371/journal.pone.0054108.g002
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the serine allele had a 60% response rate to pramipexole
compared to only a 13% response rate in glycine allele carriers.
The effect of ser9gly on pramipexole response in mood disorders is
unknown but merits investigation.
Additional comments
The ser9gly variant appears to be pleiotropic and is a well
established risk factor for movement disorders such as tardive
dyskinesia [66,67] and essential tremor [47,68]. It has not only
been implicated in mood disorders and addiction, but personality
traits [69], schizophrenia [70,71], cognition [72], autism [73],
obsessive compulsive disorder [74], and response to clozapine
[75,76] in the context of psychosis. Conceivably, the ser9gly
polymorphism is capable of modulating a variety of functions and
circuits in which the D3 receptor plays an integral role, perhaps
explaining evidence for a recent positive selection sweep in favor of
the ser9 allele in European [70] and east Asian populations [71].
The wide range of phenotypes implicated in these genetic
association studies together with our results, which are suggestive
of a large effect size for the ser9gly variant, raise the question of
why the evidence for the D3 receptor involvement in reward and
depression-like behavior has not been more robust in the
preclinical literature. One possibility is that in contrast to monkeys
and primates, which carry the gly9 allele, there is no equivalent
polymorphism in mice or rats (figure S3). A D3 receptor knockout
may not be adequate to model the change in D3 receptor function
associated with the serine-glycine substitution. However, future
studies with a gly9 knock-in mouse or rat may provide valuable
insight into the role of the D3 receptor in addiction, mood
disorders, and psychosis.
One weakness of our study is the modest sample size, which
may have led to type I or II error. Although large sample sizes are
uncommon in PET studies because of cost and radiation exposure,
PET has an advantage over magnetic resonance imaging because
it allows a particular molecular target to be assayed directly. Thus
it is likely that true signals can be detected with relatively small
sample sizes. For example, in a sample of HCs (n= 25) and
patients with BD (n= 16) and MDD (n= 17), we previously found
a significant association between a non-synonymous polymor-
phism in the galactose mutarotase gene and serotonin transporter
BP in the context of a genome-wide association study [77].
Nevertheless, interactions between ser9gly and functional poly-
morphisms in DRD2 (C957T and rs1076560), which have been
previously associated with D2/3 receptor binding at rest [2,3],
would be interesting to examine in a larger sample.
The order of tasks (sensorimotor and reward task) was not
counterbalanced because the PET-[11C]raclopride B/I approach
permits imaging in only two conditions per scan session and a
behavioral reward-induced increase in DA release that displaces
[11C]raclopride can persist for 45 minutes. Thus the task order
was fixed so that the unpredicted reward condition, which we
expected to increase phasic DA release, always followed the
sensorimotor baseline task. Nevertheless, order effects were
unlikely to have affected the assessments of DA release induced
by the unpredicted reward task because the [11C]raclopride BP
obtained during the sensorimotor control task did not differ
significantly across genotypes. Future studies potentially may
explore the issue of order effects by including a second scan session
in which the BP obtained during the sensorimotor control task is
compared to the BP obtained during a resting baseline condition
(i.e., such a design can address order effects by counterbalancing
the order of the session comprised of the resting baseline and
sensorimotor task with the session comprised of the sensorimotor
task and unpredicted reward task).
Another limitation of our paper concerns the limited temporal
resolution of PET, which does not allow a distinction to be made
between the effect of the ser9gly DRD3 SNP on DA release
associated with anticipation of reward versus DA release associated
with receipt of reward.
Future multi-modal imaging studies that combine functional
MRI (fMRI) and [11C]raclopride PET data may provide further
insights into the role of the ser9gly polymorphism in modulating
reward-associated DA-release. A number of studies have success-
fully applied multi-modal imaging in order to examine the
relationship between serotonergic function [78,79] or dopamine
storage capacity [80] and the hemodynamic response to affective
stimuli in regions such as the amygdala. Conceivably, a gambling
task similar to the one used in this study could be implemented in a
cohort of subjects who complete both [11C]raclopride PET and
fMRI. It may also be important to examine the effect of the ser9gly
SNP on baseline D3 receptor binding using the selective D3
ligand, [11C]-(+)-PHNO.
In summary, the present study demonstrates that the DRD3
ser9gly variant influences in vivo DA release in the context of
unpredicted reward, a finding with potentially important implica-
tions for the pathophysiology and treatment of addiction and
mood disorders.
Supporting Information
Table S1 Linear Regression Showing Effects of Genetically-
Defined African and European Ancestry on Raclopride Binding.
(DOC)
Figure S1 During each trial, subjects were presented
four distinct pictures (apple, grape, cherry, bell)
presented in a ‘‘slot-machine’’ motif. (Adapted from
Martin-Soelch et al. 2012). Subjects were asked to choose one of
the four with a button press on a four-button response box. This
response was followed by a 500 msec delay. In the rewarded trials
a one-dollar bill appeared for 1,000 msec and subjects heard the
sound of an opening cash-register door. These monetary gains
were provided in a pseudo-randomized order with an average of
one reward every fourth trial. In the sensorimotor control trials,
subjects instead were presented with a meaningless symbol
accompanied by a clicking sound on every fourth trial. After
being made aware of the trial outcome, subjects were presented
their running total of earnings for 1,000 msec. Displaying the
actual balance account prevented rapid discounting of the rewards
presented. At the end of each trial subjects viewed a blank screen
for 1,000 msec. During the reward task subjects were unaware of
which trial or picture would lead to the receipt of a reward, except
that the same picture could not provide a reward in two
consecutive trials. Subjects thus were instructed not to select the
same picture more than twice in a row.
(TIFF)
Figure S2 The figure shows the distribution of the
percentage change in D2/3 receptor binding stratified
according to genotype. Figure A illustrates the change in D2/3
receptor binding in the middle caudate in the healthy subjects.
Figure B shows the change in D2/3 receptor binding in the middle
caudate in the MDD subjects. Figure C illustrates the change in
D2/3 receptor binding in the ventral striatum in healthy subjects.
Figure D shows the change in D2/3 receptor binding in the
ventral striatum in MDD patients.
(TIFF)
Figure S3 The figures illustrate the position of the
rs6280 SNP in the DRD3 gene (top) and the conservation
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among species of the amino acid at residue 9, highlight-
ed within the red box (bottom). Mice have a serine allele at
residue 9, while rats carry a threonine allele. The glycine allele is
present in the other species listed in the figure, including humans.
The data were obtained from the National Center for Biotech-
nology Information (www.ncbi.nlm.nih.gov).
(TIF)
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